Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421265 | PMC |
| http://dx.doi.org/10.1093/ndtplus/sfn090 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Lactic acidosis associated with metformin: A case series from the Saint-Denis hospital].
Rev Med Interne
January 2025
Service de médecine interne, hôpital Louis-Mourier, Colombes, France.
Introduction: Metformin is a first line treatment for type II diabetes. Cases of metformin-associated lactic acidosis are regularly reported. A direct causal link between metformin overdose and lactic acidosis is not clearly established.
View Article and Find Full Text PDFSimultaneous Treatment of Two Severe Acute Intoxication and Acute Kidney Injury.
Semin Dial
December 2024
Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Extracorporeal therapies could be required for treatment of life-threatening severe acute intoxication. We present the case of an 82-year-old patient admitted to our Nephrology Unit because of metformin-associated lactic acidosis (MALA) and acute kidney injury (AKI stage III AKIN criteria). The patient also presented severe intoxication of digoxin and apixaban.
View Article and Find Full Text PDFInfluence of gut bile acid composition on the glucose-lowering effect and safety of metformin.
Br J Clin Pharmacol
December 2024
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Republic of Korea.
Article Synopsis
- The study investigates how cholestyramine, a bile acid sequestrant, influences the effectiveness of metformin in lowering blood glucose levels by altering intestinal bile acid composition.
- It involved healthy male adults in a two-period crossover design, where participants received metformin alone in the first period and with cholestyramine in the second, measuring various glucose response parameters.
- Results showed that cholestyramine further decreased the glucose-lowering effects of metformin and improved the associated side effect of diarrhea in some participants.
[Acute blindness in a patient with metformin-associated lactic acidosis].
Ned Tijdschr Geneeskd
October 2024
Zaans Medisch Centrum, afd. Interne Geneeskunde, Zaandam.
Lactic acidosis is a rare metabolic complication that can occur in patients with diabetes mellitus type 2 who use metformin. We discuss a 79-year old woman with metformin-associated lactic acidosis (MALA) and acute kidney injury based on gastroenteritis. Patient reported acute blindness which in literature is described as a rare presentation of a metabolic acidosis (regardless of its underlying cause).
View Article and Find Full Text PDFTrends in Antidiabetic Drug Use and Safety of Metformin in Diabetic Patients with Varying Degrees of Chronic Kidney Disease from 2010 to 2021 in Korea: Retrospective Cohort Study Using the Common Data Model.
Pharmaceuticals (Basel)
October 2024
Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.
Article Synopsis
- The study aimed to analyze trends in the use of antidiabetic medications in patients with chronic kidney disease (CKD) and identify the risk of metformin-associated lactic acidosis (MALA).
- It involved a review of electronic medical records from 2010 to 2021, focusing on patients over 18 with both CKD and type 2 diabetes who had been on antidiabetic drugs for at least 30 days.
- Metformin was the most commonly prescribed drug for earlier stages of CKD, but its use declined significantly in advanced stages, while SGLT2 and DPP-4 inhibitors saw increased prescriptions, highlighting varying treatment patterns and low MALA risk in CKD patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!